Skip to content
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Biotricity Inc. BTCY

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$16.0M
▲ 16.0% YoY
$-2.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We developed our Bioflux® (“Bioflux”) COM technology, which has received clearance from the U.S. Food and Drug Administration (“FDA”), comprised of a monitoring device and software components, which we made available to the market under limited release on April 6, 2018, to assess, establish and develop sales processes and market dynamics. We currently have 46 full-time employees and approximately 20 consultants who are based in our offices located in Silicon Valley, California and Toronto, Canada. Late in 2024, we launched the cellular version of that same device, the Biocore Pro, which is now our flagship technology.

Written from the business description in Biotricity Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 July 2026. Every sentence was checked against that document before publication.

Growth

USD 16.0M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 16.0 · Net income -2.4
10M20M-15M-30M
20142017202020232025
Compound annual growth
+18.4%
+36.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +36.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−15 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 10.6% · Net -15.0%
-1000%-2000%
201420192025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Net buybacks $ Dividends $
FY2020 · Dividends 602969.0 · Net buybacks ·
250000.0500000.0
20192020

Total assetsUSD 6.4M
EquityUSD -34.7M
CashUSD 149,789.00
Gross debtUSD 2.0M
Net debtUSD 1.9M
Current ratio0.16×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BTCY, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.0◌◌◌◌
Operating income $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌◌−0.0◌◌◌◌◌◌◌
EPS, diluted $−0.12−0.56−1.66−2.26◌−0.44−0.32−0.26−0.29−0.30−0.24−0.02
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout %—————−4−2—————
ROE % — not applicable: negative equity————————————
Shares out B0.030.030.010.050.050.040.030.030.020.020.020.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 55 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. 11 checks were skipped: revenue is not tagged before 2018. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inNevada
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image